Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | GAS5, NCRNA00030, SNHG2, ENST00000456293.5, GAS5-007 |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, RNAi, Western blot, Luciferase reporter assay etc. |
| Sample | cell lines (Sk-Hep-1, BEL-7404, Huh7) |
| Expression Pattern | up-regulated |
| Function Description | rs145204276 may contribute to hepatocarcinogenesis by affecting methylation status of the GAS5 promoter and subsequently its transcriptional activity thus serving as a potential therapy target for HCC. |
| Pubmed ID | 26163879 |
| Year | 2015 |
| Title | Association between indel polymorphism in the promoter region of lncRNA GAS5 and the risk of hepatocellular carcinoma. |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |